Key Developments: Aspen Technology Inc (AZPN.O)

AZPN.O on Nasdaq

36.69USD
24 Dec 2014
Price Change (% chg)

$0.28 (+0.77%)
Prev Close
$36.41
Open
$36.58
Day's High
$37.20
Day's Low
$36.57
Volume
201,231
Avg. Vol
790,685
52-wk High
$48.39
52-wk Low
$31.57

Search Stocks

Latest Key Developments (Source: Significant Developments)

Aspen Technology Inc Issues Q3 2013 Guidance In Line With Analysts' Estimates; Raises FY 2013 Guidance-Conference Call
Tuesday, 29 Jan 2013 09:30pm EST 

Aspen Technology Inc announced that for the third quarter of 2013, it expects revenue in the range of $71 million to $74 million and non-GAAP operating income of $6.5 million to $8.5 million and non-GAAP EPS of $0.04 to $0.05. On a GAAP basis the Company expect operating income of $3 million to $5 million and EPS of $0.01 to $0.02. For fiscal 2013, it is increasing revenue guidance to $295 million to $302 million, an increase from previous target of $285 million to $295 million , non-GAAP operating income guidance to $46 million to $53 million, up from prior guidance of $36 million to $46 million and non-GAAP earnings per share (EPS) in the range of $0.28 to $0.33, an increase from $0.21 to $0.27. The Company expect GAAP operating income in the range of $31 million to $38 million, which is an increase from prior guidance of $20 million to $30 million and GAAP net income of approximately $17 million to $21 million or $0.18 to $0.22 per share, which is an increase versus prior expectation of net income of $10 million to $16 million or $0.10 to $0.17 per share. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report revenue of $73 million, EBIT of $7.4 million, EPS of $0.05 for the third quarter of 2013; and revenues of $299 million, EBIT of $47 million, EPS of $0.32 for fiscal 2013.  Full Article

UPDATE 1-Aspen, Cipla win share of $860 mln S.Africa AIDS drug tender

JOHANNESBURG, Dec 24 - South Africa will spend 10 billion rand ($860 million) between 2015 and 2017 on life-prolonging HIV/AIDS treatment drugs, health authorities said on Wednesday, as studies show the prevalence of the virus is rising.

Search Stocks